Table 1 Characteristics of SSc patients
Characteristics | SSc (n = 44), mean ± SD or n (%) |
|---|---|
Demographics and FRAX-related parameters | |
Age (years) | 64.1 ± 9.0 |
BMI (kg/m2) | 25.4 ± 3.9 |
Patients in menopause | 31 (70.4) |
Menopausal age (years) | 46.1 ± 3.2 |
Duration of menopause (years) | 21.5 ± 7.8 |
Current smoking | 1 (2.2) |
Alcohol intake | 5 (11.3) |
History of fracture | 19 (43.2) |
Family history of hip fracture | 4 (9) |
Disease characteristics | |
Disease duration (years) | 18.0 ± 5.9 |
Type of disease | |
Limited cutaneous | 33 (75) |
Diffuse cutaneous | 11 (25) |
Current digital ulcers | 13 (29.5) |
Organ involvement | |
Interstitial lung disease | 35 (79.5) |
Cardiac involvement | 29 (65.9) |
Pulmonary arterial hypertension | 3 (6.8) |
Dysphagia and esophageal reflux disease | 25 (56.8) |
Malabsorption syndrome | 13 (29.5) |
Serological tests | |
Antinuclear antibody (ANA) positivity | 33 (75) |
Anticentromere antibody (ACA) positivity | 7 (15.9) |
Anti-topoisomerase I antibody (Scl-70) positivity | 11 (25) |
Treatment for SSc manifestations | |
Corticosteroid (short-term) | 17 (38.6) |
Cyclophosphamide | 8 (18.1) |
Other immunosuppressive drugs (MTX, AZA) | 13 (29.5) |
Rituximab | 1 (2.2) |
Treatment for OP | |
Calcium supplementation | 32 (72.7) |
Vitamin D supplementation | 32 (72.7) |
Bisphosphonates | 16 (36.3) |
Denosumab | 2 (4.5) |